MX2021011376A - Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos. - Google Patents
Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos.Info
- Publication number
- MX2021011376A MX2021011376A MX2021011376A MX2021011376A MX2021011376A MX 2021011376 A MX2021011376 A MX 2021011376A MX 2021011376 A MX2021011376 A MX 2021011376A MX 2021011376 A MX2021011376 A MX 2021011376A MX 2021011376 A MX2021011376 A MX 2021011376A
- Authority
- MX
- Mexico
- Prior art keywords
- sultona
- isothiazolidine
- butan
- dioxide
- derivatives containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824190P | 2019-03-26 | 2019-03-26 | |
| PCT/IB2020/052825 WO2020194209A1 (en) | 2019-03-26 | 2020-03-25 | Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011376A true MX2021011376A (es) | 2021-10-13 |
Family
ID=70190042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011376A MX2021011376A (es) | 2019-03-26 | 2020-03-25 | Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220202787A1 (https=) |
| EP (1) | EP3947392B1 (https=) |
| JP (1) | JP7461369B2 (https=) |
| KR (1) | KR20210142689A (https=) |
| CN (1) | CN113614090B (https=) |
| AU (1) | AU2020250026B2 (https=) |
| BR (1) | BR112021018692A2 (https=) |
| CA (1) | CA3134653A1 (https=) |
| DK (1) | DK3947392T3 (https=) |
| ES (1) | ES2987625T3 (https=) |
| FI (1) | FI3947392T3 (https=) |
| HR (1) | HRP20240633T1 (https=) |
| HU (1) | HUE067396T2 (https=) |
| LT (1) | LT3947392T (https=) |
| MX (1) | MX2021011376A (https=) |
| PL (1) | PL3947392T3 (https=) |
| PT (1) | PT3947392T (https=) |
| RS (1) | RS65531B1 (https=) |
| SI (1) | SI3947392T1 (https=) |
| WO (1) | WO2020194209A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| HRP20250197T1 (hr) | 2018-12-18 | 2025-04-11 | Novartis Ag | Derivati rapamicina |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| JP2023028473A (ja) * | 2021-08-19 | 2023-03-03 | 日本マイクロバイオファーマ株式会社 | エベロリムスの製造方法 |
| GB202415232D0 (en) | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| CA2257803C (en) * | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| ATE264863T1 (de) * | 1999-08-24 | 2004-05-15 | Ariad Gene Therapeutics Inc | 28-epirapaloge |
| US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| AR112834A1 (es) * | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
-
2020
- 2020-03-25 US US17/442,733 patent/US20220202787A1/en active Pending
- 2020-03-25 RS RS20240515A patent/RS65531B1/sr unknown
- 2020-03-25 JP JP2021557231A patent/JP7461369B2/ja active Active
- 2020-03-25 FI FIEP20717312.1T patent/FI3947392T3/fi active
- 2020-03-25 HU HUE20717312A patent/HUE067396T2/hu unknown
- 2020-03-25 MX MX2021011376A patent/MX2021011376A/es unknown
- 2020-03-25 WO PCT/IB2020/052825 patent/WO2020194209A1/en not_active Ceased
- 2020-03-25 CA CA3134653A patent/CA3134653A1/en active Pending
- 2020-03-25 KR KR1020217033691A patent/KR20210142689A/ko active Pending
- 2020-03-25 PL PL20717312.1T patent/PL3947392T3/pl unknown
- 2020-03-25 SI SI202030428T patent/SI3947392T1/sl unknown
- 2020-03-25 CN CN202080022154.4A patent/CN113614090B/zh active Active
- 2020-03-25 BR BR112021018692A patent/BR112021018692A2/pt unknown
- 2020-03-25 PT PT207173121T patent/PT3947392T/pt unknown
- 2020-03-25 EP EP20717312.1A patent/EP3947392B1/en active Active
- 2020-03-25 ES ES20717312T patent/ES2987625T3/es active Active
- 2020-03-25 HR HRP20240633TT patent/HRP20240633T1/hr unknown
- 2020-03-25 LT LTEPPCT/IB2020/052825T patent/LT3947392T/lt unknown
- 2020-03-25 AU AU2020250026A patent/AU2020250026B2/en active Active
- 2020-03-25 DK DK20717312.1T patent/DK3947392T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7461369B2 (ja) | 2024-04-03 |
| KR20210142689A (ko) | 2021-11-25 |
| EP3947392B1 (en) | 2024-02-28 |
| CN113614090A (zh) | 2021-11-05 |
| RS65531B1 (sr) | 2024-06-28 |
| SI3947392T1 (sl) | 2024-07-31 |
| EP3947392A1 (en) | 2022-02-09 |
| HUE067396T2 (hu) | 2024-10-28 |
| PT3947392T (pt) | 2024-05-14 |
| AU2020250026B2 (en) | 2023-08-10 |
| AU2020250026A1 (en) | 2021-09-23 |
| LT3947392T (lt) | 2024-05-27 |
| BR112021018692A2 (pt) | 2021-11-23 |
| WO2020194209A1 (en) | 2020-10-01 |
| JP2022527270A (ja) | 2022-06-01 |
| US20220202787A1 (en) | 2022-06-30 |
| HRP20240633T1 (hr) | 2024-08-02 |
| FI3947392T3 (fi) | 2024-05-08 |
| CA3134653A1 (en) | 2020-10-01 |
| PL3947392T3 (pl) | 2024-07-15 |
| CN113614090B (zh) | 2026-04-28 |
| ES2987625T3 (es) | 2024-11-15 |
| DK3947392T3 (da) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011376A (es) | Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos. | |
| CL2021003191A1 (es) | Inhibidores de tead y usos de los mismos | |
| CL2021000361A1 (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
| CO2021016015A2 (es) | Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas | |
| CO2021002382A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
| MX2019003254A (es) | Compuestos y metodos para la modulacion de ido y tdo, e indicaciones de estos. | |
| UY37848A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| CL2019002609A1 (es) | Compuestos heterocíclicos útiles como inhibidores dobles atx/ca. | |
| MX2013006847A (es) | Compuesto heterociclico fusionado y su uso para el control de plagas. | |
| CL2022000556A1 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
| ECSP19051352A (es) | Inhibidores selectivos de jak1 | |
| CO2022000612A2 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos | |
| ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| MX380753B (es) | Lactamas bicíclicas y métodos de uso de las mismas. | |
| UY29176A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos. | |
| CO2022002000A2 (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
| DOP2010000022A (es) | Derivados de pirimidina 934 | |
| ECSP22026478A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| CO2022000422A2 (es) | Inhibidores de enzimas | |
| PY2039849A (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos | |
| CL2022002661A1 (es) | Derivados de benzodiazepinas como pam de gaba a gamma1 | |
| CO2020016080A2 (es) | Compuestos |